IRAK3 modulates downstream innate immune signalling through its guanylate cyclase activity

Interleukin-1 receptor associated kinase 3 (IRAK3) is a cytoplasmic homeostatic mediator of inflammatory responses and is potentially useful as a prognostic marker in inflammation. IRAK3 inhibits signalling cascades downstream of myddosome complexes associated with toll like receptors. IRAK3 contain...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2019-10, Vol.9 (1), p.15468-12, Article 15468
Hauptverfasser: Freihat, L. A., Wheeler, J. I., Wong, A., Turek, I., Manallack, D. T., Irving, H. R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 12
container_issue 1
container_start_page 15468
container_title Scientific reports
container_volume 9
creator Freihat, L. A.
Wheeler, J. I.
Wong, A.
Turek, I.
Manallack, D. T.
Irving, H. R.
description Interleukin-1 receptor associated kinase 3 (IRAK3) is a cytoplasmic homeostatic mediator of inflammatory responses and is potentially useful as a prognostic marker in inflammation. IRAK3 inhibits signalling cascades downstream of myddosome complexes associated with toll like receptors. IRAK3 contains a death domain that interacts with other IRAK family members, a pseudokinase domain and a C-terminus domain involved with tumour necrosis factor receptor associated factor 6 (TRAF6). Previous bioinformatic studies revealed that IRAK3 contained a guanylate cyclase centre in its pseudokinase domain but its role in IRAK3 action is unresolved. We demonstrate that wildtype IRAK3 is capable of producing cGMP. Furthermore, we show that a specific point mutation in the guanylate cyclase centre reduced cGMP production. Cells containing toll like receptor 4 and a nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB) reporter system were transfected with IRAK3 or mutant IRAK3 proteins. Cell-permeable cGMP treatment of untransfected control cells suppresses downstream signalling through modulation of the NFĸB in the presence of lipopolysaccharides. Cells transfected with wildtype IRAK3 also suppress lipopolysaccharide induced NFĸB activity in the absence of exogenous cGMP. Lipopolysaccharide induced NFĸB activity was not suppressed in cells transfected with the IRAK3 mutant with reduced cGMP-generating capacity. Whereas in the presence of exogenously applied cell-permeable cGMP the IRAK3 mutant was able to retain its function by suppressing lipopolysaccharide induced NFĸB activity. Furthermore, increasing the amount of membrane permeable cGMP did not affect IRAK3’s ability to reduce NFĸB activity. These results suggest that cGMP generated by IRAK3 may be involved in regulatory function of the protein where the presence of cGMP may selectively affect downstream signalling pathway(s) by modulating binding and/or activity of nearby proteins that interact in the inflammatory signalling cascade.
doi_str_mv 10.1038/s41598-019-51913-3
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820782</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2310419410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-ed786c8429847380e07eae2d59fe13069476928afd5ec59787260d558c8eb9ab3</originalsourceid><addsrcrecordid>eNp9kU9vFSEUxYnR2Kb2C7gwJG7cjPJ3gI1J01Tb2MTE6MYN4TH3zaOZgQpMzfv20k6t1YVsINzfPRfOQeglJW8p4fpdEVQa3RFqOkkN5R1_gg4ZEbJjnLGnj84H6LiUK9KWZEZQ8xwdcNr3ghJziL5ffDn5xPGchmVyFQoe0s9YagY34xBju8JhnpcIuIQxumkKccR1l9My7nCoBY-Li_vbVuz3fnIFsPM13IS6f4Gebd1U4Ph-P0LfPpx9PT3vLj9_vDg9uey8UKJ2MCjdey2Y0UJxTYAocMAGabZAOemNUL1h2m0HCV4apRXrySCl9ho2xm34EXq_6l4vmxkGD7FmN9nrHGaX9za5YP-uxLCzY7qxvWZEadYE3twL5PRjgVLtHIqHaXIR0lIs45T0SjRDG_r6H_QqLbn5slLN3WZro9hK-ZxKybB9eAwl9jY9u6ZnW3r2Lj3LW9Orx994aPmdVQP4CpRWiiPkP7P_I_sLfbGmFQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2310419410</pqid></control><display><type>article</type><title>IRAK3 modulates downstream innate immune signalling through its guanylate cyclase activity</title><source>Nature Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Springer Nature OA/Free Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Freihat, L. A. ; Wheeler, J. I. ; Wong, A. ; Turek, I. ; Manallack, D. T. ; Irving, H. R.</creator><creatorcontrib>Freihat, L. A. ; Wheeler, J. I. ; Wong, A. ; Turek, I. ; Manallack, D. T. ; Irving, H. R.</creatorcontrib><description>Interleukin-1 receptor associated kinase 3 (IRAK3) is a cytoplasmic homeostatic mediator of inflammatory responses and is potentially useful as a prognostic marker in inflammation. IRAK3 inhibits signalling cascades downstream of myddosome complexes associated with toll like receptors. IRAK3 contains a death domain that interacts with other IRAK family members, a pseudokinase domain and a C-terminus domain involved with tumour necrosis factor receptor associated factor 6 (TRAF6). Previous bioinformatic studies revealed that IRAK3 contained a guanylate cyclase centre in its pseudokinase domain but its role in IRAK3 action is unresolved. We demonstrate that wildtype IRAK3 is capable of producing cGMP. Furthermore, we show that a specific point mutation in the guanylate cyclase centre reduced cGMP production. Cells containing toll like receptor 4 and a nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB) reporter system were transfected with IRAK3 or mutant IRAK3 proteins. Cell-permeable cGMP treatment of untransfected control cells suppresses downstream signalling through modulation of the NFĸB in the presence of lipopolysaccharides. Cells transfected with wildtype IRAK3 also suppress lipopolysaccharide induced NFĸB activity in the absence of exogenous cGMP. Lipopolysaccharide induced NFĸB activity was not suppressed in cells transfected with the IRAK3 mutant with reduced cGMP-generating capacity. Whereas in the presence of exogenously applied cell-permeable cGMP the IRAK3 mutant was able to retain its function by suppressing lipopolysaccharide induced NFĸB activity. Furthermore, increasing the amount of membrane permeable cGMP did not affect IRAK3’s ability to reduce NFĸB activity. These results suggest that cGMP generated by IRAK3 may be involved in regulatory function of the protein where the presence of cGMP may selectively affect downstream signalling pathway(s) by modulating binding and/or activity of nearby proteins that interact in the inflammatory signalling cascade.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-019-51913-3</identifier><identifier>PMID: 31664109</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/95 ; 631/250/516/1909 ; 631/80/86/820 ; 82 ; 82/80 ; 96 ; Amino Acid Sequence ; Animals ; C-Terminus ; Cell Line ; Cyclic GMP ; Cyclic GMP - metabolism ; Generating capacity ; Guanylate cyclase ; Guanylate Cyclase - chemistry ; Guanylate Cyclase - metabolism ; Humanities and Social Sciences ; Humans ; Immunity, Innate ; Inflammation ; Interleukin 1 ; Interleukin-1 Receptor-Associated Kinases - chemistry ; Interleukin-1 Receptor-Associated Kinases - genetics ; Interleukin-1 Receptor-Associated Kinases - metabolism ; IRAK protein ; Kinases ; Lipopolysaccharides ; Lymphocytes B ; multidisciplinary ; Point Mutation ; Science ; Science (multidisciplinary) ; Sequence Homology, Amino Acid ; Signal Transduction ; Toll-like receptors ; TRAF6 protein ; Tumor necrosis factor ; Tumors</subject><ispartof>Scientific reports, 2019-10, Vol.9 (1), p.15468-12, Article 15468</ispartof><rights>The Author(s) 2019</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-ed786c8429847380e07eae2d59fe13069476928afd5ec59787260d558c8eb9ab3</citedby><cites>FETCH-LOGICAL-c474t-ed786c8429847380e07eae2d59fe13069476928afd5ec59787260d558c8eb9ab3</cites><orcidid>0000-0002-1514-0909</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820782/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820782/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31664109$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Freihat, L. A.</creatorcontrib><creatorcontrib>Wheeler, J. I.</creatorcontrib><creatorcontrib>Wong, A.</creatorcontrib><creatorcontrib>Turek, I.</creatorcontrib><creatorcontrib>Manallack, D. T.</creatorcontrib><creatorcontrib>Irving, H. R.</creatorcontrib><title>IRAK3 modulates downstream innate immune signalling through its guanylate cyclase activity</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Interleukin-1 receptor associated kinase 3 (IRAK3) is a cytoplasmic homeostatic mediator of inflammatory responses and is potentially useful as a prognostic marker in inflammation. IRAK3 inhibits signalling cascades downstream of myddosome complexes associated with toll like receptors. IRAK3 contains a death domain that interacts with other IRAK family members, a pseudokinase domain and a C-terminus domain involved with tumour necrosis factor receptor associated factor 6 (TRAF6). Previous bioinformatic studies revealed that IRAK3 contained a guanylate cyclase centre in its pseudokinase domain but its role in IRAK3 action is unresolved. We demonstrate that wildtype IRAK3 is capable of producing cGMP. Furthermore, we show that a specific point mutation in the guanylate cyclase centre reduced cGMP production. Cells containing toll like receptor 4 and a nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB) reporter system were transfected with IRAK3 or mutant IRAK3 proteins. Cell-permeable cGMP treatment of untransfected control cells suppresses downstream signalling through modulation of the NFĸB in the presence of lipopolysaccharides. Cells transfected with wildtype IRAK3 also suppress lipopolysaccharide induced NFĸB activity in the absence of exogenous cGMP. Lipopolysaccharide induced NFĸB activity was not suppressed in cells transfected with the IRAK3 mutant with reduced cGMP-generating capacity. Whereas in the presence of exogenously applied cell-permeable cGMP the IRAK3 mutant was able to retain its function by suppressing lipopolysaccharide induced NFĸB activity. Furthermore, increasing the amount of membrane permeable cGMP did not affect IRAK3’s ability to reduce NFĸB activity. These results suggest that cGMP generated by IRAK3 may be involved in regulatory function of the protein where the presence of cGMP may selectively affect downstream signalling pathway(s) by modulating binding and/or activity of nearby proteins that interact in the inflammatory signalling cascade.</description><subject>13/95</subject><subject>631/250/516/1909</subject><subject>631/80/86/820</subject><subject>82</subject><subject>82/80</subject><subject>96</subject><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>C-Terminus</subject><subject>Cell Line</subject><subject>Cyclic GMP</subject><subject>Cyclic GMP - metabolism</subject><subject>Generating capacity</subject><subject>Guanylate cyclase</subject><subject>Guanylate Cyclase - chemistry</subject><subject>Guanylate Cyclase - metabolism</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Immunity, Innate</subject><subject>Inflammation</subject><subject>Interleukin 1</subject><subject>Interleukin-1 Receptor-Associated Kinases - chemistry</subject><subject>Interleukin-1 Receptor-Associated Kinases - genetics</subject><subject>Interleukin-1 Receptor-Associated Kinases - metabolism</subject><subject>IRAK protein</subject><subject>Kinases</subject><subject>Lipopolysaccharides</subject><subject>Lymphocytes B</subject><subject>multidisciplinary</subject><subject>Point Mutation</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Sequence Homology, Amino Acid</subject><subject>Signal Transduction</subject><subject>Toll-like receptors</subject><subject>TRAF6 protein</subject><subject>Tumor necrosis factor</subject><subject>Tumors</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU9vFSEUxYnR2Kb2C7gwJG7cjPJ3gI1J01Tb2MTE6MYN4TH3zaOZgQpMzfv20k6t1YVsINzfPRfOQeglJW8p4fpdEVQa3RFqOkkN5R1_gg4ZEbJjnLGnj84H6LiUK9KWZEZQ8xwdcNr3ghJziL5ffDn5xPGchmVyFQoe0s9YagY34xBju8JhnpcIuIQxumkKccR1l9My7nCoBY-Li_vbVuz3fnIFsPM13IS6f4Gebd1U4Ph-P0LfPpx9PT3vLj9_vDg9uey8UKJ2MCjdey2Y0UJxTYAocMAGabZAOemNUL1h2m0HCV4apRXrySCl9ho2xm34EXq_6l4vmxkGD7FmN9nrHGaX9za5YP-uxLCzY7qxvWZEadYE3twL5PRjgVLtHIqHaXIR0lIs45T0SjRDG_r6H_QqLbn5slLN3WZro9hK-ZxKybB9eAwl9jY9u6ZnW3r2Lj3LW9Orx994aPmdVQP4CpRWiiPkP7P_I_sLfbGmFQ</recordid><startdate>20191029</startdate><enddate>20191029</enddate><creator>Freihat, L. A.</creator><creator>Wheeler, J. I.</creator><creator>Wong, A.</creator><creator>Turek, I.</creator><creator>Manallack, D. T.</creator><creator>Irving, H. R.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1514-0909</orcidid></search><sort><creationdate>20191029</creationdate><title>IRAK3 modulates downstream innate immune signalling through its guanylate cyclase activity</title><author>Freihat, L. A. ; Wheeler, J. I. ; Wong, A. ; Turek, I. ; Manallack, D. T. ; Irving, H. R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-ed786c8429847380e07eae2d59fe13069476928afd5ec59787260d558c8eb9ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>13/95</topic><topic>631/250/516/1909</topic><topic>631/80/86/820</topic><topic>82</topic><topic>82/80</topic><topic>96</topic><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>C-Terminus</topic><topic>Cell Line</topic><topic>Cyclic GMP</topic><topic>Cyclic GMP - metabolism</topic><topic>Generating capacity</topic><topic>Guanylate cyclase</topic><topic>Guanylate Cyclase - chemistry</topic><topic>Guanylate Cyclase - metabolism</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Immunity, Innate</topic><topic>Inflammation</topic><topic>Interleukin 1</topic><topic>Interleukin-1 Receptor-Associated Kinases - chemistry</topic><topic>Interleukin-1 Receptor-Associated Kinases - genetics</topic><topic>Interleukin-1 Receptor-Associated Kinases - metabolism</topic><topic>IRAK protein</topic><topic>Kinases</topic><topic>Lipopolysaccharides</topic><topic>Lymphocytes B</topic><topic>multidisciplinary</topic><topic>Point Mutation</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Sequence Homology, Amino Acid</topic><topic>Signal Transduction</topic><topic>Toll-like receptors</topic><topic>TRAF6 protein</topic><topic>Tumor necrosis factor</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Freihat, L. A.</creatorcontrib><creatorcontrib>Wheeler, J. I.</creatorcontrib><creatorcontrib>Wong, A.</creatorcontrib><creatorcontrib>Turek, I.</creatorcontrib><creatorcontrib>Manallack, D. T.</creatorcontrib><creatorcontrib>Irving, H. R.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Freihat, L. A.</au><au>Wheeler, J. I.</au><au>Wong, A.</au><au>Turek, I.</au><au>Manallack, D. T.</au><au>Irving, H. R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IRAK3 modulates downstream innate immune signalling through its guanylate cyclase activity</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2019-10-29</date><risdate>2019</risdate><volume>9</volume><issue>1</issue><spage>15468</spage><epage>12</epage><pages>15468-12</pages><artnum>15468</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Interleukin-1 receptor associated kinase 3 (IRAK3) is a cytoplasmic homeostatic mediator of inflammatory responses and is potentially useful as a prognostic marker in inflammation. IRAK3 inhibits signalling cascades downstream of myddosome complexes associated with toll like receptors. IRAK3 contains a death domain that interacts with other IRAK family members, a pseudokinase domain and a C-terminus domain involved with tumour necrosis factor receptor associated factor 6 (TRAF6). Previous bioinformatic studies revealed that IRAK3 contained a guanylate cyclase centre in its pseudokinase domain but its role in IRAK3 action is unresolved. We demonstrate that wildtype IRAK3 is capable of producing cGMP. Furthermore, we show that a specific point mutation in the guanylate cyclase centre reduced cGMP production. Cells containing toll like receptor 4 and a nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB) reporter system were transfected with IRAK3 or mutant IRAK3 proteins. Cell-permeable cGMP treatment of untransfected control cells suppresses downstream signalling through modulation of the NFĸB in the presence of lipopolysaccharides. Cells transfected with wildtype IRAK3 also suppress lipopolysaccharide induced NFĸB activity in the absence of exogenous cGMP. Lipopolysaccharide induced NFĸB activity was not suppressed in cells transfected with the IRAK3 mutant with reduced cGMP-generating capacity. Whereas in the presence of exogenously applied cell-permeable cGMP the IRAK3 mutant was able to retain its function by suppressing lipopolysaccharide induced NFĸB activity. Furthermore, increasing the amount of membrane permeable cGMP did not affect IRAK3’s ability to reduce NFĸB activity. These results suggest that cGMP generated by IRAK3 may be involved in regulatory function of the protein where the presence of cGMP may selectively affect downstream signalling pathway(s) by modulating binding and/or activity of nearby proteins that interact in the inflammatory signalling cascade.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31664109</pmid><doi>10.1038/s41598-019-51913-3</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-1514-0909</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2019-10, Vol.9 (1), p.15468-12, Article 15468
issn 2045-2322
2045-2322
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820782
source Nature Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; Springer Nature OA/Free Journals; Free Full-Text Journals in Chemistry
subjects 13/95
631/250/516/1909
631/80/86/820
82
82/80
96
Amino Acid Sequence
Animals
C-Terminus
Cell Line
Cyclic GMP
Cyclic GMP - metabolism
Generating capacity
Guanylate cyclase
Guanylate Cyclase - chemistry
Guanylate Cyclase - metabolism
Humanities and Social Sciences
Humans
Immunity, Innate
Inflammation
Interleukin 1
Interleukin-1 Receptor-Associated Kinases - chemistry
Interleukin-1 Receptor-Associated Kinases - genetics
Interleukin-1 Receptor-Associated Kinases - metabolism
IRAK protein
Kinases
Lipopolysaccharides
Lymphocytes B
multidisciplinary
Point Mutation
Science
Science (multidisciplinary)
Sequence Homology, Amino Acid
Signal Transduction
Toll-like receptors
TRAF6 protein
Tumor necrosis factor
Tumors
title IRAK3 modulates downstream innate immune signalling through its guanylate cyclase activity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T14%3A46%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IRAK3%20modulates%20downstream%20innate%20immune%20signalling%20through%20its%20guanylate%20cyclase%20activity&rft.jtitle=Scientific%20reports&rft.au=Freihat,%20L.%20A.&rft.date=2019-10-29&rft.volume=9&rft.issue=1&rft.spage=15468&rft.epage=12&rft.pages=15468-12&rft.artnum=15468&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-019-51913-3&rft_dat=%3Cproquest_pubme%3E2310419410%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2310419410&rft_id=info:pmid/31664109&rfr_iscdi=true